Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 17Carcinoma, Hepatocellular 5Neoplasms 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Liver Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uveal Melanoma 2Stomach Neoplasms 2Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasm Metastasis 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Basal Cell 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1

Interventions

pembrolizumab 243Carboplatin 211Pemetrexed 177Cisplatin 131Paclitaxel 113Nivolumab 101Docetaxel 87osimertinib 85durvalumab 78Specimen Handling 56atezolizumab 55Gemcitabine 52Drug Therapy 52Magnetic Resonance Spectroscopy 50Radiosurgery 48Radiotherapy 47Ipilimumab 41130-nm albumin-bound paclitaxel 39cemiplimab 38Bevacizumab 34Cetuximab 30tislelizumab 29amivantamab 22Taxes 22Platinum Compounds 20Blood Specimen Collection 20Immunotherapy 18Immune Checkpoint Inhibitors 18Radiation 17Erlotinib Hydrochloride 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × relatlimab × 1 year × Clear all
NCT05176483 2026-05-27

STELLAR-002

Exelixis

Phase 1 Recruiting
1,314 enrolled
GastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT06561386 2026-05-20

RELATIVITY1093

Bristol-Myers Squibb

Phase 3 Recruiting
1,000 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04623775 2025-10-20

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb

Phase 2 Active not recruiting
468 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡